Clinical Trial Update: Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients [Phase 1]

View source ↗

Summary

Phase 1 trial assessing EBV-specific cytotoxic T cells engineered to express a GD-2 chimeric antigen receptor in neuroblastoma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GD-2 CAR T cells (EBV-specific CTLs expressing GD-2 CAR)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED